echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Arvinas Announces Detailed Results of Androgen Receptor PROTAC Protein Degrader

    Arvinas Announces Detailed Results of Androgen Receptor PROTAC Protein Degrader

    • Last Update: 2022-05-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, Arvinas announced updated results from Phase 1 and Phase 2 clinical trials of its androgen receptor (AR)-targeting PROTAC protein degrader, bavdegalutamide (ARV-110)


    Bavdegalutamide is an AR-targeting PROTAC protein degrader that recruits E3 ubiquitin ligases to the vicinity of ARs, tags ARs with ubiquitin, and guides them for proteasomal degradation


    The latest trial results showed that bavdegalutamide reduced prostate-specific antigen (PSA) levels by ≥50% (PSA50) in 46% of all patients with AR T878X/H875Y mutations in phase 1 and 2 clinical trials


    Image source: Arvinas official website

    Furthermore, among patients with the AR T878X/H875Y mutation, 6 of 7 patients whose tumors could be assessed for clinical response using RECIST experienced tumor shrinkage, including two with confirmed partial responses


    Image source: Arvinas official website

    Arvinas said that more than 10% of mCRPC patients carry AR T878X/H875Y mutations, and blood-based circulating tumor DNA (ctDNA) testing can identify these patients and use bavdegalutamide to precisely treat them


    In terms of safety, bavdegalutamide showed a manageable tolerability profile at the recommended dose in phase 2 clinical trials


    Arvinas plans to initiate discussions with the US FDA to explore the potential of bavdegalutamide to treat patients with molecularly defined mCRPC through the accelerated approval pathway


    References:

    [1] Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer.


    [2] Bavdegalutamide (ARV-110): Phase 1 Dose Escalation and Interim ARDENT Phase 2 Dose Expansion Trial Results.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.